

February 7, 2019

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

**Sub: Glenmark Pharmaceuticals receives tentative ANDA approval for Fulvestrant Injection,
250 mg/5 mL (50 mg/mL)**

Dear Sir,

With reference to the subject mentioned above, kindly find attached media release which is self explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH
VINAYAK
KUBER

Digitally signed by
HARISH VINAYAK KUBER
Date: 2019.02.07
09:16:07 +05'30'

Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Press Release

For Immediate Release

Glenmark Pharmaceuticals receives tentative ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)

Mumbai, India, February 7, 2019: Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL), a generic version of FASLODEX^{®1} Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP.

According to IQVIA[™] sales data for the 12 month period ending December 2018, the FASLODEX[®] Injection, 250 mg/5 mL (50 mg/mL) market² achieved annual sales of approximately \$533.3 million*.

Glenmark's current portfolio consists of 148 products authorized for distribution in the U.S. marketplace and 54 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

¹All brand names and trademarks are the property of their respective owners.

²Market includes brand and all available therapeutic equivalents

*IQVIA[™] National Sales Perspectives: Retail & Non-Retail, December 2018

--End--

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2018). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:

Isha Trivedi

Glenmark, Mumbai, India

Tel: +91 22 4018 9801

Email: corpcomm@glenmarkpharma.com